{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T08:55:31Z","timestamp":1776329731086,"version":"3.50.1"},"reference-count":36,"publisher":"Baskent University","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Exp Clin Transplant"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.6002\/ect.2021.0003","type":"journal-article","created":{"date-parts":[[2021,8,18]],"date-time":"2021-08-18T03:06:35Z","timestamp":1629255995000},"page":"69-76","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of 2 Different Doses of Antithymocyte Globulin in Conditioning Regimens for Haploidentical Hematopoietic Stem Cell Transplantation"],"prefix":"10.6002","volume":"20","author":[{"given":"Mingyang","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaosheng","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yujie","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaohui","family":"Sui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xianghua","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peipei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongzhi","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4021","reference":[{"key":"ref0","doi-asserted-by":"publisher","unstructured":"Wingard JR, Majhail NS, Brazauskas R, et al. Long-term survival and late deaths after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2011;29(16):2230-2239. doi:10.1200\/JCO.2010.33.7212","DOI":"10.1200\/JCO.2010.33.7212"},{"key":"ref1","doi-asserted-by":"publisher","unstructured":"2. Soiffer RJ, Lerademacher J, Ho V, et al. Impact of immune modulation with anti-T-cell antibodies on the outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation for hematologic malignancies. Blood. 2011;117(25):6963-6970. doi:10.1182\/blood-2011-01-332007","DOI":"10.1182\/blood-2011-01-332007"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"3. Remberger M, Ringden O, Hagglund H, et al. A high antithymocyte globulin dose increases the risk of relapse after reduced intensity conditioning HSCT with unrelated donors. Clin Transplant. 2013;27(4):E368-E374. doi:10.1111\/ctr.12131","DOI":"10.1111\/ctr.12131"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"4. Bacigalupo A, Lamparelli T, Bruzzi P, et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood. 2001;98(10):2942-2947. doi:10.1182\/blood.v98.10.2942","DOI":"10.1182\/blood.V98.10.2942"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"5. Wang Y, Fu HX, Liu DH, et al. Influence of two different doses of antithymocyte globulin in patients with standard-risk disease following haploidentical transplantation: a randomized trial. Bone Marrow Transplant. 2014;49(3):426-433. doi:10.1038\/bmt.2013.191","DOI":"10.1038\/bmt.2013.191"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"6. Kroger N, Solano C, Wolschke C, et al. Antilymphocyte globulin for prevention of chronic graft-versus-host disease. N Engl J Med. 2016;374(1):43-53. doi:10.1056\/NEJMoa1506002","DOI":"10.1056\/NEJMoa1506002"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"7. Chang YJ, Wang Y, Mo XD, et al. Optimal dose of rabbit thymoglobulin in conditioning regimens for unmanipulated, haploidentical, hematopoietic stem cell transplantation: Long-term outcomes of a prospective randomized trial. Cancer. 2017;123(15):2881-2892. doi:10.1002\/cncr.30540","DOI":"10.1002\/cncr.30540"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"8. Walker I, Panzarella T, Couban S, et al. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomised, controlled, open-label, phase 3, multicentre trial. Lancet Oncol. 2016;17(2):164-173. doi:10.1016\/S1470-2045(15)00462-3","DOI":"10.1016\/S1470-2045(15)00462-3"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"9. Nishihori T, Al-Kadhimi Z, Hamadani M, Kharfan-Dabaja MA. Antithymocyte globulin in allogeneic hematopoietic cell transplantation: benefits and limitations. Immunotherapy. 2016;8(4):435-447. doi:10.2217\/imt.15.128","DOI":"10.2217\/imt.15.128"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"10. Lu DP, Dong L, Wu T, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched\/haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood. 2006;107(8):3065-3073. doi:10.1182\/blood-2005-05-2146","DOI":"10.1182\/blood-2005-05-2146"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"11. Han LJ, Wang Y, Fan ZP, et al. Haploidentical transplantation compared with matched sibling and unrelated donor transplantation for adults with standard-risk acute lymphoblastic leukaemia in first complete remission. Br J Haematol. 2017;179(1):120-130. doi:10.1111\/bjh.14854","DOI":"10.1111\/bjh.14854"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"12. Glucksberg H, Storb R, Fefer A, et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation. 1974;18(4):295-304. doi:10.1097\/00007890-197410000-00001","DOI":"10.1097\/00007890-197410000-00001"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"13. Filipovich AH, Weisdorf D, Pavletic S, et al. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant. 2005;11(12):945-956. doi:10.1016\/j.bbmt.2005.09.004","DOI":"10.1016\/j.bbmt.2005.09.004"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"14. Armand P, Kim HT, Logan BR, et al. Validation and refinement of the Disease Risk Index for allogeneic stem cell transplantation. Blood. 2014;123(23):3664-3671. doi:10.1182\/blood-2014-01-552984","DOI":"10.1182\/blood-2014-01-552984"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"15. Passweg JR, Baldomero H, Bader P, et al. Use of haploidentical stem cell transplantation continues to increase: the 2015 European Society for Blood and Marrow Transplant activity survey report. Bone Marrow Transplant. 2017;52(6):811-817. doi:10.1038\/bmt.2017.34","DOI":"10.1038\/bmt.2017.34"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"16. Wang Y, Liu QF, Xu LP, et al. Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood. 2015;125(25):3956-3962. doi:10.1182\/blood-2015-02-627786","DOI":"10.1182\/blood-2015-02-627786"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"17. Wang Y, Liu QF, Xu LP, et al. Haploidentical versus matched-sibling transplant in adults with Philadelphia-negative high-risk acute lymphoblastic leukemia: a biologically phase III randomized study. Clin Cancer Res. 2016;22(14):3467-3476. doi:10.1158\/1078-0432.CCR-15-2335","DOI":"10.1158\/1078-0432.CCR-15-2335"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"18. Xu LP, Jin S, Wang SQ, et al. Upfront haploidentical transplant for acquired severe aplastic anemia: registry-based comparison with matched related transplant. J Hematol Oncol. 2017;10(1):25. doi:10.1186\/s13045-017-0398-y","DOI":"10.1186\/s13045-017-0398-y"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"19. Wang Y, Wang HX, Lai YR, et al. Haploidentical transplant for myelodysplastic syndrome: registry-based comparison with identical sibling transplant. Leukemia. 2016;30(10):2055-2063. doi:10.1038\/leu.2016.110","DOI":"10.1038\/leu.2016.110"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"20. Liu Z, Zhang Y, Xiao H, et al. Cotransplantation of bone marrow-derived mesenchymal stem cells in haploidentical hematopoietic stem cell transplantation in patients with severe aplastic anemia: an interim summary for a multicenter phase II trial results. Bone Marrow Transplant. 2017;52(5):704-710. doi:10.1038\/bmt.2016.347","DOI":"10.1038\/bmt.2016.347"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"21. Lin X, Lu ZG, Song CY, et al. Long-term outcome of HLA-haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion based on an FBCA conditioning regimen for hematologic malignancies. Bone Marrow Transplant. 2015;50(8):1092-1097. doi:10.1038\/bmt.2015.108","DOI":"10.1038\/bmt.2015.108"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"22. Li Y, Duan F, Xiao H, et al. Therapeutic outcomes of haploidentical allogeneic hematopoietic stem cell transplantation in patients with severe aplastic anemia: a multicenter study. Transplantation. 2018;102(10):1724-1731. doi:10.1097\/TP.0000000000002200","DOI":"10.1097\/TP.0000000000002200"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"23. Lin R, Wang Y, Huang F, et al. Two dose levels of rabbit antithymocyte globulin as graft-versus-host disease prophylaxis in haploidentical stem cell transplantation: a multicenter randomized study. BMC Med. 2019;17(1):156. doi:10.1186\/s12916-019-1393-7","DOI":"10.1186\/s12916-019-1393-7"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"24. Salem G, Ruppert AS, Elder P, et al. Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplant. Leuk Lymphoma. 2015;56(4):1058-1065. doi:10.3109\/10428194.2014.956314","DOI":"10.3109\/10428194.2014.956314"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"25. Hamadani M, Blum W, Phillips G, et al. Improved nonrelapse mortality and infection rate with lower dose of antithymocyte globulin in patients undergoing reduced-intensity conditioning allogeneic transplantation for hematologic malignancies. Biol Blood Marrow Transplant. 2009;15(11):1422-1430. doi:10.1016\/j.bbmt.2009.07.006","DOI":"10.1016\/j.bbmt.2009.07.006"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"26. Kennedy VE, Chen H, Savani BN, et al. Optimizing antithymocyte globulin dosing for unrelated donor allogeneic hematopoietic cell transplantation based on recipient absolute lymphocyte count. Biol Blood Marrow Transplant. 2018;24(1):150-155. doi:10.1016\/j.bbmt.2017.08.029","DOI":"10.1016\/j.bbmt.2017.08.029"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"27. Storb R, Gyurkocza B, Storer BE, et al. Graft-versus-host disease and graft-versus-tumor effects after allogeneic hematopoietic cell transplantation. J Clin Oncol. 2013;31(12):1530-1538. doi:10.1200\/JCO.2012.45.0247","DOI":"10.1200\/JCO.2012.45.0247"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"28. Mohty M. Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond. Leukemia. 2007;21(7):1387-1394. doi:10.1038\/sj.leu.2404683","DOI":"10.1038\/sj.leu.2404683"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"29. Liu J, Xu LP, Bian Z, et al. Differential impact of two doses of antithymocyte globulin conditioning on lymphocyte recovery upon haploidentical hematopoietic stem cell transplantation. J Transl Med. 2015;13:391. doi:10.1186\/s12967-015-0748-x","DOI":"10.1186\/s12967-015-0748-x"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"30. Binkert L, Medinger M, Halter JP, et al. Lower dose anti-thymocyte globulin for GvHD prophylaxis results in improved survival after allogeneic stem cell transplantation. Bone Marrow Transplant. 2015;50(10):1331-1336. doi:10.1038\/bmt.2015.148","DOI":"10.1038\/bmt.2015.148"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"31. Kedi W, Dongjiang X, Zhi L, Yan G, Kun J, Jianrong S. The rational specimen for the quantitative detection of Epstein-Barr virus DNA load. Clin Chem Lab Med. 2019;57(5):759-765. doi:10.1515\/cclm-2018-0733","DOI":"10.1515\/cclm-2018-0733"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"32. Ruf S, Behnke-Hall K, Gruhn B, et al. Comparison of six different specimen types for Epstein-Barr viral load quantification in peripheral blood of pediatric patients after heart transplantation or after allogeneic hematopoietic stem cell transplantation. J Clin Virol. 2012;53(3):186-194. doi:10.1016\/j.jcv.2011.11.010","DOI":"10.1016\/j.jcv.2011.11.010"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"33. Fu H, Xu L, Liu D, et al. Late-onset hemorrhagic cystitis after haploidentical hematopoietic stem cell transplantation in patients with advanced leukemia: differences in ATG dosage are key. Int J Hematol. 2013;98(1):89-95. doi:10.1007\/s12185-013-1350-8","DOI":"10.1007\/s12185-013-1350-8"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"34. Wakamatsu M, Terakura S, Ohashi K, et al. Impacts of thymoglobulin in patients with acute leukemia in remission undergoing allogeneic HSCT from different donors. Blood Adv. 2019;3(2):105-115. doi:10.1182\/bloodadvances.2018025643","DOI":"10.1182\/bloodadvances.2018025643"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"35. Admiraal R, van Kesteren C, Jol-van der Zijde CM, et al. Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis. Lancet Haematol. 2015;2(5):e194-e203. doi:10.1016\/S2352-3026(15)00045-9","DOI":"10.1016\/S2352-3026(15)00045-9"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"36. Bosch M, Dhadda M, Hoegh-Petersen M, et al. Immune reconstitution after anti-thymocyte globulin-conditioned hematopoietic cell transplantation. Cytotherapy. 2012;14(10):1258-1275. doi:10.3109\/14653249.2012.715243","DOI":"10.3109\/14653249.2012.715243"}],"container-title":["Experimental and Clinical Transplantation"],"original-title":[],"deposited":{"date-parts":[[2022,1,24]],"date-time":"2022-01-24T03:04:01Z","timestamp":1642993441000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.ectrx.org\/detail\/archive\/2022\/20\/1\/0\/69\/0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"URL":"https:\/\/doi.org\/10.6002\/ect.2021.0003","relation":{},"ISSN":["1304-0855","2146-8427"],"issn-type":[{"value":"1304-0855","type":"print"},{"value":"2146-8427","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1]]}}}